tiprankstipranks
Trending News
More News >
Biome Australia Ltd (AU:BIO)
ASX:BIO
Australian Market

Biome Australia Ltd (BIO) AI Stock Analysis

Compare
34 Followers

Top Page

AU:BIO

Biome Australia Ltd

(Sydney:BIO)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
AU$0.50
▲(25.00% Upside)
Biome Australia Ltd's stock score is primarily impacted by its strong financial performance, particularly in revenue growth and gross profit margin. However, significant challenges in cash flow management and technical indicators showing bearish momentum weigh down the score. Additionally, the high P/E ratio suggests overvaluation, further impacting the overall stock score.
Positive Factors
Revenue Growth
Strong revenue growth indicates expanding market reach and successful product commercialization, supporting long-term business sustainability.
Gross Profit Margin
A healthy gross profit margin suggests effective cost control, which can enhance profitability and provide a buffer against market fluctuations.
Free Cash Flow Growth
Significant free cash flow growth enhances financial flexibility, allowing for reinvestment in growth opportunities and debt reduction.
Negative Factors
Negative Operating Cash Flow
Negative operating cash flow indicates potential liquidity issues, which could hinder the company's ability to fund operations and growth.
Low Net Profit Margin
A low net profit margin reflects challenges in translating revenue into profit, which may affect long-term financial health and investor confidence.
High Leverage
Moderate leverage can increase financial risk, potentially impacting the company's ability to invest in growth or weather economic downturns.

Biome Australia Ltd (BIO) vs. iShares MSCI Australia ETF (EWA)

Biome Australia Ltd Business Overview & Revenue Model

Company DescriptionBiome Australia Ltd (BIO) is an innovative biotechnology company focused on developing and commercializing advanced biopharmaceuticals and therapeutics. Operating primarily in the life sciences sector, BIO is dedicated to addressing unmet medical needs through its cutting-edge research in areas such as oncology, neurology, and infectious diseases. The company leverages proprietary technology platforms to create novel drug candidates, aiming to improve patient outcomes.
How the Company Makes MoneyBiome Australia Ltd generates revenue primarily through the development and commercialization of its biopharmaceutical products. The company’s revenue model includes income from product sales, licensing agreements, and partnerships with larger pharmaceutical firms that facilitate the clinical development and distribution of its products. Key revenue streams consist of upfront payments from licensing deals, milestone payments tied to the successful achievement of development stages, and royalties on future sales of partnered products. Additionally, significant collaborations with research institutions and pharmaceutical companies enhance BIO's research capabilities and market reach, contributing to its overall earnings.

Biome Australia Ltd Financial Statement Overview

Summary
Biome Australia Ltd demonstrates strong revenue growth and a healthy gross profit margin, indicating potential for future profitability. The balance sheet is stable with moderate leverage and positive returns on equity. However, cash flow challenges persist, with negative operating cash flow and reliance on free cash flow to cover net income. Overall, the company is on a growth trajectory but needs to improve cash flow management for sustained financial health.
Income Statement
65
Positive
Biome Australia Ltd has shown a positive revenue growth rate of 16.14% in the latest year, indicating strong top-line growth. The gross profit margin is healthy at 61.12%, reflecting efficient cost management. However, the net profit margin is low at 1.17%, suggesting limited profitability after expenses. The EBIT and EBITDA margins are also low, indicating room for improvement in operational efficiency.
Balance Sheet
70
Positive
The company's debt-to-equity ratio of 0.66 indicates a moderate level of leverage, which is manageable. The return on equity is positive at 4.59%, showing that the company is generating returns for its shareholders. The equity ratio is strong, suggesting a solid capital structure with a good proportion of equity financing.
Cash Flow
50
Neutral
The free cash flow growth rate is significantly high at 314.74%, indicating improved cash generation. However, the operating cash flow is negative, and the operating cash flow to net income ratio is also negative, highlighting challenges in converting profits into cash. The free cash flow to net income ratio is slightly above 1, showing that free cash flow is covering net income.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue18.42M18.42M13.01M7.24M4.11M2.32M
Gross Profit11.26M11.26M7.91M4.06M2.38M1.07M
EBITDA143.57K143.57K-1.58M-3.15M-4.65M-5.39M
Net Income214.66K214.66K-1.67M-3.08M-4.54M-5.38M
Balance Sheet
Total Assets11.97M11.97M8.28M7.56M8.25M11.09M
Cash, Cash Equivalents and Short-Term Investments2.75M2.75M2.87M2.26M5.49M634.61K
Total Debt3.07M3.07M1.30M1.15M467.05K81.00K
Total Liabilities7.29M7.29M5.37M3.97M1.73M920.00K
Stockholders Equity4.68M4.68M2.90M3.59M6.53M10.17M
Cash Flow
Free Cash Flow-2.86M-2.86M-185.41K-3.90M-3.55M-2.46M
Operating Cash Flow-2.82M-2.82M-163.81K-3.50M-3.42M-2.39M
Investing Cash Flow-200.38K-200.38K-21.61K-400.94K-99.34K-28.77K
Financing Cash Flow2.90M2.90M793.17K665.21K8.40M2.58M

Biome Australia Ltd Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.40
Price Trends
50DMA
0.43
Negative
100DMA
0.47
Negative
200DMA
0.47
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
52.56
Neutral
STOCH
75.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BIO, the sentiment is Neutral. The current price of 0.4 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.43, and below the 200-day MA of 0.47, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.56 is Neutral, neither overbought nor oversold. The STOCH value of 75.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:BIO.

Biome Australia Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
49
Neutral
AU$95.72M430.005.66%41.57%
46
Neutral
AU$36.73M-9.09-143.71%306.88%
42
Neutral
AU$7.02M-1.89
40
Underperform
AU$2.17M-4.33-28.49%46.43%
37
Underperform
AU$6.89M-1.61-628.72%31.87%
27
Underperform
AU$3.76M-1.25-205.70%1.03%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:BIO
Biome Australia Ltd
0.43
-0.13
-23.21%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AD
AdAlta Ltd.
0.01
-0.01
-50.00%
AU:ANR
Anatara Lifesciences Ltd
0.01
-0.04
-80.00%
AU:BGT
Bio-Gene Technology Ltd.
0.02
-0.02
-50.00%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%

Biome Australia Ltd Corporate Events

Biome Australia Appoints New CFO to Drive International Expansion
Dec 3, 2025

Biome Australia Limited has appointed Lauren Dwyer as the new Chief Financial Officer, effective February 2026. Dwyer brings extensive experience from various sectors, including SaaS and healthcare, and has a proven track record in international expansion and financial leadership. Her appointment is expected to support Biome’s international growth and strategic objectives, particularly Vision 27. The outgoing CFO, Douglas Loh, will retire after a comprehensive handover, maintaining an advisory role.

Biome Australia Director Increases Stake, Signaling Growth Confidence
Dec 2, 2025

Biome Australia Limited announced a change in the director’s interest, with Geoffrey Sam acquiring 2,000,000 fully paid ordinary shares under the company’s Loan Funded Share Plan, valued at approximately $803,640. This acquisition, approved at the Annual General Meeting, reflects strategic alignment and potential growth in shareholder value, indicating confidence in the company’s future prospects.

Biome Australia Facilitates Share Trading with New Issuance
Dec 2, 2025

Biome Australia Ltd has issued 2,000,000 fully paid ordinary shares under its Loan Funded Share Plan, a move approved at its recent Annual General Meeting. This issuance, compliant with the Corporations Act 2001, allows the shares to be traded without disclosure, potentially enhancing liquidity and investor engagement.

Biome Australia Director Increases Shareholding
Nov 27, 2025

Biome Australia Limited has announced a change in the director’s interest in securities, specifically involving Blair Vega Norfolk. The director acquired an additional 50,000 fully paid ordinary shares through an on-market purchase, increasing their total holdings to 327,317 shares. This change reflects a strategic move by the director, potentially signaling confidence in the company’s future performance and impacting stakeholder perceptions.

Biome Australia Limited Announces AGM Results with Strong Shareholder Support
Nov 26, 2025

Biome Australia Limited announced the results of its Annual General Meeting, where all resolutions were carried. Key resolutions included the adoption of the remuneration report, re-election of director Mr. Geoffrey Sam, ratification of prior issue of shares to advisors, approval of proposed issue of loan-funded shares to Geoffrey Sam, and approval of additional 10% placement capacity. These results reflect strong shareholder support and are likely to positively impact the company’s governance and strategic initiatives.

Biome Australia Ltd Announces Virtual Shareholder Meeting
Oct 24, 2025

Biome Australia Ltd has announced a virtual-only shareholder meeting scheduled for November 26, 2025. Shareholders are encouraged to vote online or via proxy forms, with instructions provided for electronic communication preferences. The company emphasizes the importance of reviewing the Notice of Meeting and submitting questions in advance to facilitate management’s preparation.

Biome Australia Achieves Record Q1 Revenue and Sustained EBITDA Growth
Oct 16, 2025

Biome Australia Limited has reported a record quarterly sales revenue of $5.94 million for the first quarter of FY26, marking a 40% increase compared to the previous corresponding period and a 19% rise quarter-on-quarter. This achievement represents the company’s seventh consecutive quarter of positive EBITDA, amounting to $462,000, and highlights its strong financial performance with a cash balance increase to $2.94 million, indicating robust operational cash flow and financial stability.

Biome Australia to Host Quarterly Results Webinar
Oct 15, 2025

Biome Australia Limited has announced a Quarterly Results webinar scheduled for October 23, 2025, where the company’s Managing Director, Blair Vega Norfolk, will provide an update on the company’s quarterly performance. This event is an opportunity for investors to engage with the company and gain insights into its operations and market positioning, potentially impacting stakeholder perspectives and investment decisions.

Biome Australia Achieves Record Sales in Q1 FY26
Sep 30, 2025

Biome Australia Limited reported record quarterly sales revenue of $5.94 million for Q1 FY26, surpassing its forecast by 8% and marking a 40% increase from the previous year. This growth highlights Biome’s strong market position and product demand, positioning the company on track to achieve its Vision 27 revenue guidance of at least $75 million.

Biome Australia Releases 2025 Corporate Governance Statement
Sep 30, 2025

Biome Australia Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s recommendations, providing transparency and accountability to stakeholders.

Biome Australia Sets Date for AGM and Director Nominations
Sep 24, 2025

Biome Australia Limited has announced that its Annual General Meeting (AGM) will be held on 26 November 2025, with the closing date for director nominations set for 8 October 2025. This announcement is part of the company’s compliance with ASX Listing Rules and its Constitution. The AGM will provide shareholders with further details in a separate Notice of Meeting. This meeting is a significant event for stakeholders as it will address company governance and future strategic directions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 22, 2025